[ATNM] Actinium Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 0.97 Change: -0 (-0.5%)
Ext. hours: Change: 0 (0%)

chart ATNM

Refresh chart

Strongest Trends Summary For ATNM

ATNM is in the long-term down -67% below S&P in 2 years and down -98% below S&P in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Actinium Pharmaceuticals, Inc., a biotechnology company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform. Its products include Bismab-A for acute myeloid leukemia; Actimab-A, an antibody-drug construct that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia; and Iomab-B, an antibody-drug construct used in myeloconditioning for hematopoietic stem cells transplantation in various indications. The company was formerly known as Cactus Ventures, Inc. and changed its name to Actinium Pharmaceuticals, Inc. in April 2013. Actinium Pharmaceuticals, Inc. was founded in 2000 and is based in New York, New York.

Fundamental Ratios
Shares Outstanding EPS-0.54 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-2.07
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-55.16% ROE-67.28% ROI
Current Ratio5.52 Quick Ratio Long Term Debt/Equity Debt Ratio0.22
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities18.39 M Cash From Investing Activities Cash From Operating Activities-5.81 M Gross Profit
Net Profit-3.07 M Operating Profit-7.87 M Total Assets20.06 M Total Current Assets19.92 M
Total Current Liabilities3.61 M Total Debt190 K Total Liabilities3.61 M Total Revenue
Technical Data
High 52 week0.82 Low 52 week0.2 Last close0.2 Last change-0.51%
RSI9.3 Average true range0.01 Beta1.17 Volume288.91 K
Simple moving average 20 days-9.47% Simple moving average 50 days-11.28% Simple moving average 200 days-48.79%
Performance Data
Performance Week-1.99% Performance Month-14.72% Performance Quart-14.35% Performance Half-60.84%
Performance Year-75.01% Performance Year-to-date-49.1% Volatility daily2.73% Volatility weekly6.11%
Volatility monthly12.52% Volatility yearly43.36% Relative Volume353.16% Average Volume632.42 K
New High New Low

News

2020-04-24 17:15:00 | Actinium Pharmaceuticals, Inc. Announces Closing of $31.6 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares

2020-04-21 23:35:00 | Actinium Pharmaceuticals, Inc. Announces Pricing of $27.5 Million Public Offering

2020-04-21 16:01:00 | Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering

2020-04-16 07:00:00 | Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020

2020-04-12 09:02:20 | Can Actinium Pharmaceuticals NYSEMKT:ATNM Afford To Invest In Growth?

2020-03-06 10:56:03 | Actinium Treats First Patient in AML Study on Actimab-A Combo

2020-03-05 07:30:00 | Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia

2020-02-26 07:33:00 | Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients

2020-02-25 09:33:02 | Actinium ATNM to Report Q4 Earnings: What's in the Cards?

2020-02-21 07:30:00 | Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR TCT

2020-02-13 08:03:00 | Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation

2020-02-05 17:50:10 | Actinium Pharmaceuticals ATNM Gains But Lags Market: What You Should Know

2020-02-05 08:03:00 | Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

2020-01-30 17:45:10 | Actinium Pharmaceuticals ATNM Stock Sinks As Market Gains: What You Should Know

2020-01-13 12:00:05 | Actinium ATNM Upgraded to Strong Buy: Here's Why

2020-01-13 07:15:17 | One Thing To Remember About The Actinium Pharmaceuticals, Inc. NYSEMKT:ATNM Share Price

2020-01-13 07:03:00 | Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma

2020-01-07 07:03:00 | Actinium Pharmaceuticals, Inc. to Present at 2020 Biotech Showcase™

2020-01-03 11:30:04 | Is Actinium Pharmaceuticals ATNM Outperforming Other Medical Stocks This Year?

2020-01-02 09:29:02 | Tilray TLRY in Focus: Stock Moves 9% Higher

2019-12-22 17:08:58 | Hedge Funds Have Never Been More Bullish On Actinium Pharmaceuticals Inc ATNM

2019-12-09 06:10:00 | Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting

2019-12-09 06:00:00 | Actinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

2019-12-07 08:35:07 | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

2019-12-01 09:30:15 | The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

2019-11-20 09:00:02 | What Makes Actinium ATNM a New Buy Stock

2019-11-07 16:05:00 | Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference

2019-11-06 09:15:00 | Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019

2019-11-06 09:00:00 | Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019

2019-10-28 08:20:00 | Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment

2019-10-15 10:48:01 | What Kind Of Investor Owns Most Of Actinium Pharmaceuticals, Inc. NYSEMKT:ATNM?

2019-09-30 08:00:00 | Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa

2019-09-23 08:00:00 | Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts

2019-09-16 08:00:00 | Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment

2019-07-23 08:00:00 | Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B

2019-07-17 12:56:33 | How Actinium Pharmaceuticals, Inc. NYSEMKT:ATNM Can Impact Your Portfolio Volatility

2019-07-11 08:00:00 | Actinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial Caregivers

2019-06-26 08:00:00 | Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

2019-06-25 08:00:00 | Actinium Presents New Data Demonstrating Effective Lymphodepletion with Lutetium-177 for CAR-T at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

2019-06-20 08:00:00 | Actinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

2019-06-04 08:00:00 | Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting

2019-05-24 13:40:28 | Investors Who Bought Actinium Pharmaceuticals NYSEMKT:ATNM Shares Five Years Ago Are Now Down 98%

2019-05-16 08:00:00 | Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting

2019-05-07 08:00:00 | Actinium Announces Appointment of Niva Almaula, Ph.D. as Chief Business Officer

2019-04-18 09:00:00 | Actinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants

2019-04-17 16:01:00 | Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants

2019-04-08 08:00:00 | Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium

2019-04-04 09:57:01 | The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

2019-04-03 09:16:01 | Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

2019-04-03 08:00:00 | Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR